FDA flags cancer-causing impurity in common heartburn drugs

The FDA is warning patients and healthcare providers that some ranitidine medicines, common heartburn drugs, contain a potentially cancer-causing impurity. 

Advertisement

The rantitide drugs were found to contain N-nitrosodimethylamine, classified as a probable human carcinogen.

The FDA warned that Sanofi’s popular brand-name drug Zantac was one of the drugs known to contain this impurity. Ranitidine is a histamine-2 blocker, which decreases the amount of acid created by the stomach. Ranitidine is both an over-the-counter and prescription drug. 

News of the impurity in a new drug comes as r the FDA has been investigating NDMA and other nitrosamine impurities in blood pressure and heart failure medicines for more than a year.  Hundreds of blood pressure medications have been recalled as a result. 

More articles on pharmacy:
Civica Rx says it isn’t afraid of competition
10 hospitals seeking pharmacy leaders
NIH probes personnel issues at its hospital pharmacy

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

How Leading Pharmacies Stay Stocked And Protect Margins

Thursday, July 23
12:00 PM - 1:00 PM CDT

Presenters: Calvin Hunsicker, SureCostChad O’Connor, SureCost

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.